Jean-Gabriel Griboul has extensive experience in venture and growth capital, private equity, public and private M&A, and capital markets transactions.
Jean-Gabriel primarily represents high-growth listed and unlisted companies, their managers, as well as the private equity and industrial investors that finance them. He has acted as principal lawyer in a significant number of early to late-stage financing rounds, M&A transactions, initial public offerings (IPOs), rights issues, tender offers, and private placements, mainly for technology and life sciences companies.
Jean-Gabriel's recent experience includes the representations of: Adikteev, Adocia, AudioValley, Cubyn, Mauna Kea Technologies, Nanobiotix, Swile, TxCell, Verimatrix, and Voluntis. His recent investor-side representations include: Alven, BNP Paribas, Bpifrance, ChapsVision, Daphni, DN Capital, Elaia Partners, ETF Partners, Eurazeo/Idinvest, Goldman Sachs, Hedosophia, Index Ventures, Invus, New Alpha Asset Management, Omnes Capital, Open CNP, Orange, Portag3 Ventures, and Seventure Partners.
Examples of the transactions in which Jean-Gabriel has acted as lead lawyer include: the Nasdaq IPO of Nanobiotix; ChapsVision tender offer on Coheris; the sale of Drivy to Getaround; financings rounds of Swile; and Orange's investments in Jumia (AIG).
- 12 avril 2018
Finale de la 4ème édition du Prix Jones Day/Paris II/ESSEC
- 7 janvier 2016
Le private equity : quelles opportunités pour 2016 ?
- University of Montpellier I (Magistère-DJCE-DESS in Business Law 2003; Master's in Business Law 2002); EDHEC Business School (M.B.A. 2001); Institut d'Etudes Politiques of Bordeaux (Sciences Po — section Service Public 1999)
- Paris Bar
Acknowledged as the #1 venture capital team in France since 2000 in top legal rankings
1st prize for IPOs and capital markets, Le Magazine des Affaires (since 2015)
Paris M&A team ranked Band 1 in "Mid-cap M&A" in France, Option Droit & Affaires (2015, 2016, 2017)
- English, French